PL370478A1 - Pochodne aminoindazolu jako inhibitory kinaz białkowych - Google Patents

Pochodne aminoindazolu jako inhibitory kinaz białkowych

Info

Publication number: PL370478A1
Authority: PL; Poland
Prior art keywords: protein; kinase inhibitors; aminoindazole derivatives; aminoindazole; derivatives
Prior art date: 2002-03-11

Application number

PL03370478A

Other languages

English (en)

Inventor

Gilles Dutruc-Rosset

Dominique Lesuisse

Thomas Rooney

Franck Halley

Original Assignee

Aventis Pharma S.A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-03-11

Filing date

2003-03-07

Publication date

2005-05-30

2003-03-07 Application filed by Aventis Pharma S.A. filed Critical Aventis Pharma S.A.

2005-05-30 Publication of PL370478A1 publication Critical patent/PL370478A1/pl

Links

YDTDKKULPWTHRV-UHFFFAOYSA-N 1H-indazol-3-amine Chemical class C1=CC=C2C(N)=NNC2=C1 YDTDKKULPWTHRV-UHFFFAOYSA-N 0.000 title 1
229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
239000003909 protein kinase inhibitor Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Immunology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Virology (AREA)
Endocrinology (AREA)
Psychology (AREA)
Communicable Diseases (AREA)
Psychiatry (AREA)
Oncology (AREA)
Tropical Medicine & Parasitology (AREA)
Hospice & Palliative Care (AREA)
AIDS & HIV (AREA)
Vascular Medicine (AREA)
Molecular Biology (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PL03370478A 2002-03-11 2003-03-07 Pochodne aminoindazolu jako inhibitory kinaz białkowych PL370478A1 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR0202997A FR2836915B1 (fr)	2002-03-11	2002-03-11	Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant

Publications (1)

Publication Number	Publication Date
PL370478A1 true PL370478A1 (pl)	2005-05-30

Family

ID=27763685

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL03370478A PL370478A1 (pl)	2002-03-11	2003-03-07	Pochodne aminoindazolu jako inhibitory kinaz białkowych

Country Status (30)

Country	Link
US (1)	US6949579B2 (pl)
EP (1)	EP1487804B1 (pl)
JP (2)	JP4648630B2 (pl)
KR (1)	KR101068770B1 (pl)
CN (2)	CN1656078A (pl)
AR (1)	AR038915A1 (pl)
AU (1)	AU2003242809B8 (pl)
BR (1)	BR0308373A (pl)
CA (1)	CA2478542C (pl)
FR (1)	FR2836915B1 (pl)
GT (1)	GT200300057A (pl)
HR (1)	HRP20040824B1 (pl)
IL (2)	IL163831A0 (pl)
JO (1)	JO2326B1 (pl)
MA (1)	MA27230A1 (pl)
ME (2)	ME00058B (pl)
MX (1)	MXPA04007478A (pl)
MY (1)	MY138269A (pl)
NO (1)	NO329384B1 (pl)
NZ (1)	NZ535147A (pl)
PA (1)	PA8568301A1 (pl)
PE (1)	PE20040155A1 (pl)
PL (1)	PL370478A1 (pl)
RS (1)	RS52396B (pl)
RU (1)	RU2345070C2 (pl)
SV (1)	SV2003001494A (pl)
TW (1)	TWI329103B (pl)
UY (1)	UY27713A1 (pl)
WO (1)	WO2003078403A2 (pl)
ZA (1)	ZA200406687B (pl)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2836914B1 (fr) *	2002-03-11	2008-03-14	Aventis Pharma Sa	Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
WO2003097610A1 (en) *	2002-05-17	2003-11-27	Pharmacia Italia S.P.A.	Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
PL374946A1 (pl) *	2002-09-05	2005-11-14	Aventis Pharma S.A.	Nowe pochodne aminoindazolu jako leki i zawierające je kompozycje farmaceutyczne
JP4401298B2 (ja) *	2002-12-02	2010-01-20	エフ．ホフマン−ラロシュアーゲー	Ｃｒｆアンタゴニストとしてのインダゾール誘導体
RU2339624C2 (ru)	2002-12-12	2008-11-27	Авентис Фарма С.А.	Производные аминоиндазолов и их применение в качестве ингибиторов киназ
FR2848554A1 (fr) *	2002-12-12	2004-06-18	Aventis Pharma Sa	Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant
US7135575B2 (en)	2003-03-03	2006-11-14	Array Biopharma, Inc.	P38 inhibitors and methods of use thereof
ES2564804T3 (es)	2004-02-12	2016-03-29	Mitsubishi Tanabe Pharma Corporation	Compuesto de indazol y uso farmacéutico del mismo
FR2871158A1 (fr) *	2004-06-04	2005-12-09	Aventis Pharma Sa	Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
GT200500208A (es)	2004-08-03	2006-03-02		Indazoles ùtiles para tratar enfermedades cardiovasculares
CA2621983A1 (en) *	2005-09-09	2007-03-22	Schering Corporation	Azafused cyclin dependent kinase inhibitors
WO2007089646A1 (en)	2006-01-31	2007-08-09	Array Biopharma Inc.	Kinase inhibitors and methods of use thereof
JP2010500300A (ja)	2006-08-08	2010-01-07	サノフィ−アベンティス	アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
WO2008074749A1 (en) *	2006-12-20	2008-06-26	Nerviano Medical Sciences S.R.L.	Indazole derivatives as kinase inhibitors for the treatment of cancer
DE102007022565A1 (de) *	2007-05-14	2008-11-20	Merck Patent Gmbh	Heterocyclische Indazolderivate
EA018503B1 (ru) *	2007-07-20	2013-08-30	НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л.	Замещенные производные индазола, активные как ингибиторы киназы
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ES2531396T3 (es)	2008-01-23	2015-03-13	Bristol Myers Squibb Co	Proceso para preparar compuestos de piridinona
WO2010003624A2 (en)	2008-07-09	2010-01-14	Sanofi-Aventis	Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en)	2008-12-08	2010-06-17	Sanofi-Aventis	A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2010069966A1 (en) *	2008-12-18	2010-06-24	Nerviano Medical Sciences S.R.L.	Substituted indazole derivatives active as kinase inhibitors
RS53830B1 (sr)	2009-04-30	2015-06-30	Glaxo Group Limited	Indazoli supstituisani oksazolom kao inhibitori pi3-kinaze
SG178880A1 (en)	2009-08-26	2012-04-27	Sanofi Sa	Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
EP2937345B1 (en)	2009-12-29	2018-03-21	Dana-Farber Cancer Institute, Inc.	Type ii raf kinase inhibitors
WO2011107494A1 (de)	2010-03-03	2011-09-09	Sanofi	Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
BR112012023021A2 (pt) *	2010-03-16	2016-05-31	Dana Farber Cancer Inst Inc	compostos de indazol e seus usos
EP2582709B1 (de)	2010-06-18	2018-01-24	Sanofi	Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
EP2651405A2 (en) *	2010-12-14	2013-10-23	Electrophoretics Limited	Casein kinase 1 (ck1 ) inhibitors
WO2012120055A1 (de)	2011-03-08	2012-09-13	Sanofi	Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de)	2011-03-08	2012-09-13	Sanofi	Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de)	2011-03-08	2012-09-13	Sanofi	Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8809324B2 (en)	2011-03-08	2014-08-19	Sanofi	Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2683703B1 (de)	2011-03-08	2015-05-27	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8846666B2 (en)	2011-03-08	2014-09-30	Sanofi	Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2766349B1 (de)	2011-03-08	2016-06-01	Sanofi	Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683704B1 (de)	2011-03-08	2014-12-17	Sanofi	Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683698B1 (de)	2011-03-08	2017-10-04	Sanofi	Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2567959B1 (en)	2011-09-12	2014-04-16	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en)	2011-09-12	2013-03-21	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP6165733B2 (ja)	2011-09-16	2017-07-19	ノバルティスアーゲー	Ｎ−置換ヘテロシクリルカルボキサミド類
EP2760862B1 (en)	2011-09-27	2015-10-21	Sanofi	6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP6106685B2 (ja)	2011-11-17	2017-04-05	ダナ−ファーバーキャンサーインスティテュート，インコーポレイテッド	Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤
RU2632659C2 (ru) *	2011-12-27	2017-10-09	Байо-Фарм Солюшнс Ко., Лтд.	Фенилкарбаматные соединения для применения в предупреждении или лечении эпилепсии
EP2909194A1 (en)	2012-10-18	2015-08-26	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinase 7 (cdk7)
US10000483B2 (en)	2012-10-19	2018-06-19	Dana-Farber Cancer Institute, Inc.	Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
USRE48175E1 (en)	2012-10-19	2020-08-25	Dana-Farber Cancer Institute, Inc.	Hydrophobically tagged small molecules as inducers of protein degradation
AU2014337044A1 (en)	2013-10-18	2016-05-05	Dana-Farber Cancer Institute, Inc.	Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2015058126A1 (en)	2013-10-18	2015-04-23	Syros Pharmaceuticals, Inc.	Heteroaromatic compounds useful for the treatment of prolferative diseases
CN103739550B (zh) *	2014-01-02	2016-06-01	中国药科大学	2,3-二甲基-6-脲-2h-吲唑类化合物及其制备方法与应用
CA2937111A1 (en) *	2014-01-24	2015-07-30	Abbvie Inc.	6-phenyl- or 6-(pyridin-3-yl)indazole derivatives and methods of use
US10231965B2 (en)	2014-02-20	2019-03-19	Ignyta, Inc.	Molecules for administration to ROS1 mutant cancer cells
WO2015164614A1 (en)	2014-04-23	2015-10-29	Dana-Farber Cancer Institute, Inc.	Janus kinase inhibitors and uses thereof
US9862688B2 (en)	2014-04-23	2018-01-09	Dana-Farber Cancer Institute, Inc.	Hydrophobically tagged janus kinase inhibitors and uses thereof
KR101731624B1 (ko) *	2014-07-01	2017-05-04	광주과학기술원	세포 리프로그래밍 유도용 조성물
EP3184521B1 (en) *	2014-08-19	2021-10-06	Shanghai Haihe Pharmaceutical Co., Ltd.	Indazole compounds as fgfr kinase inhibitors, preparation and use thereof
CN107207471B (zh)	2014-12-02	2020-06-26	伊尼塔公司	用于治疗神经母细胞瘤的组合
EP3233840B1 (en)	2014-12-16	2018-11-21	Eudendron S.r.l.	Heterocyclic derivatives modulating activity of certain protein kinases
US10870651B2 (en)	2014-12-23	2020-12-22	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinase 7 (CDK7)
CN107427521B (zh)	2015-03-27	2021-08-03	达纳-法伯癌症研究所股份有限公司	细胞周期蛋白依赖性激酶的抑制剂
CN106279119B (zh) *	2015-05-27	2020-06-16	上海海和药物研究开发有限公司	一种新型激酶抑制剂的制备及其应用
CA2986441A1 (en)	2015-06-12	2016-12-15	Dana-Farber Cancer Institute, Inc.	Combination therapy of transcription inhibitors and kinase inhibitors
GB201511382D0 (en)	2015-06-29	2015-08-12	Imp Innovations Ltd	Novel compounds and their use in therapy
WO2017044858A2 (en)	2015-09-09	2017-03-16	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinases
JP2018531266A (ja) *	2015-10-22	2018-10-25	セルビタエス．エー．	ピリドン誘導体およびキナーゼ阻害剤としてのその使用
CN105467027B (zh) *	2015-11-18	2021-09-21	北京万全德众医药生物技术有限公司	一种用气相色谱法分离测定米诺膦酸中间体有关物质的方法
BR112018012255A2 (pt)	2015-12-18	2018-12-04	Ignyta Inc	método para tratar câncer
WO2019018570A1 (en)	2017-07-19	2019-01-24	Ignyta, Inc.	PHARMACEUTICAL COMPOSITIONS CONTAINING ENTRECTINIB
CN111032646B (zh)	2017-08-01	2023-01-03	施万生物制药研发Ip有限责任公司	作为jak激酶抑制剂的吡唑并和三唑并双环化合物
WO2019077506A1 (en)	2017-10-17	2019-04-25	Ignyta, Inc.	PHARMACEUTICAL COMPOSITIONS AND SOLID GALENIC FORMS
CN110117278B (zh) *	2018-02-07	2022-07-19	石家庄以岭药业股份有限公司	烷氧基苯并五元(六元)杂环胺类化合物及其药物用途
EP3810132A4 (en)	2018-06-25	2022-06-22	Dana-Farber Cancer Institute, Inc.	TAIRE FAMILY KINASE INHIBITORS AND RELATED USES
BR112021002207A2 (pt)	2018-08-10	2021-05-04	Diapin Therapeutics, Llc	tri-peptídeos e tratamento de distúrbios metabólicos, cardiovasculares e inflamatórios
US12172995B2 (en)	2018-10-24	2024-12-24	Bristol-Myers Squibb Company	Substituted indole and indazole compounds
ES2963696T3 (es)	2018-10-24	2024-04-01	Bristol Myers Squibb Co	Compuestos diméricos de indol sustituidos
CN113164477A (zh)	2018-12-14	2021-07-23	达纳-法伯癌症研究所股份有限公司	C-jun-n-末端激酶的吡唑并吡啶抑制剂及其用途
EP3902542A4 (en)	2018-12-28	2022-09-07	Dana-Farber Cancer Institute, Inc.	CYCLIN DEPENDENT KINASE 7 INHIBITORS AND USES THEREOF
CN113498352A (zh)	2019-01-23	2021-10-12	施万生物制药研发Ip有限责任公司	作为jak抑制剂的咪唑并[1,5-a]吡啶、1,2,4-三唑并[4,3-a]吡啶和咪唑并[1,5-a]吡嗪
KR102904576B1 (ko)	2019-05-09	2025-12-24	브리스톨-마이어스 스큅 컴퍼니	치환된 벤즈이미다졸론 화합물
WO2021067326A1 (en)	2019-10-01	2021-04-08	Bristol-Myers Squibb Company	Substituted bicyclic heteroaryl compounds
CN114829350B (zh)	2019-10-04	2024-05-28	百时美施贵宝公司	经取代的咔唑化合物
CN115003666B (zh) *	2019-12-04	2025-03-21	先正达农作物保护股份公司	杀有害生物活性的稠合二环杂芳香族氨基化合物
WO2023122782A2 (en) *	2021-12-23	2023-06-29	The Katholieke Universiteit Leuven	Indoles, indazoles, and related analogs for inhibiting yap/taz-tead
CN119997982A (zh)	2022-09-09	2025-05-13	迈里克斯制药有限公司	包含nmt抑制剂的抗体药物偶联物及其用途
WO2025175264A1 (en) *	2024-02-17	2025-08-21	Padarn Therapeutics, Inc.	Inhibitors of cdk2

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3133081A (en) *		1964-05-12		J-aminoindazole derivatives
US2971842A (en) *	1956-03-21	1961-02-14	Gen Aniline & Film Corp	Light sensitive layers for photomechanical reproduction
DE1280878B (de) *	1961-11-30	1968-10-24	Smith Kline French Lab	3-Aminoindazole
GB965511A (en) *	1961-11-30	1964-07-29	Smith Kline French Lab	Improvements in or relating to 3-aminoindazole derivatives
BE626284A (pl) *	1962-04-28
DE1301319B (de) *	1965-09-08	1969-08-21	Siegfried Ag	3,5-Diaminoindazol, dessen Salze, sowie Verfahren zu deren Herstellung
US3720671A (en) *	1970-10-05	1973-03-13	Ciba Geigy Ag	Polycyclic dyestuffs
FR2111641A2 (en) *	1970-10-09	1972-06-09	Geigy Ag J R	Polycyclic cpds as dispersion dyestuffs for - hydrophobic organic fibres
DE2458965C3 (de) *	1974-12-13	1979-10-11	Bayer Ag, 5090 Leverkusen	3-Amino-indazol-N-carbonsäure-Derivate, Verfahren zu ihrer Herstellung sowie sie enthaltende Arzneimittel
JPS51143010A (en) *	1975-06-04	1976-12-09	Kao Corp	Stable bleaching detergent composition
SU742430A1 (ru) *	1978-11-09	1980-06-25	Предприятие П/Я А-7850	Способ получени 3-амино-5-нитроиндазола
EP0090972B1 (en) *	1982-03-17	1990-05-30	Asahi Kasei Kogyo Kabushiki Kaisha	Indazole derivatives
JPS58159473A (ja) *	1982-03-17	1983-09-21	Asahi Chem Ind Co Ltd	ベンゼン環置換基を有する新規な１位置換インダゾ−ル誘導体およびその製造法
KR940021073A (ko) *	1993-03-02	1994-10-17	미야베 요시가즈	알쯔하이머병의 예방 또는 치료제, 그 스크리닝 방법 및 인간 유래의 타우 단백질 키나아제 i
KR100423899B1 (ko) *	2000-05-10	2004-03-24	주식회사 엘지생명과학	세포 증식 억제제로 유용한 1,1-디옥소이소티아졸리딘을갖는 인다졸

2002
- 2002-03-11 FR FR0202997A patent/FR2836915B1/fr not_active Expired - Fee Related
2003
- 2003-02-28 PA PA20038568301A patent/PA8568301A1/es unknown
- 2003-03-03 SV SV2003001494A patent/SV2003001494A/es not_active Application Discontinuation
- 2003-03-06 JO JO200323A patent/JO2326B1/en active
- 2003-03-06 TW TW092104839A patent/TWI329103B/zh not_active IP Right Cessation
- 2003-03-07 ME MEP-2008-161A patent/ME00058B/me unknown
- 2003-03-07 IL IL16383103A patent/IL163831A0/xx unknown
- 2003-03-07 RU RU2004129780/04A patent/RU2345070C2/ru not_active IP Right Cessation
- 2003-03-07 RS YU79504A patent/RS52396B/sr unknown
- 2003-03-07 PL PL03370478A patent/PL370478A1/pl unknown
- 2003-03-07 KR KR1020047014199A patent/KR101068770B1/ko not_active Expired - Fee Related
- 2003-03-07 MX MXPA04007478A patent/MXPA04007478A/es active IP Right Grant
- 2003-03-07 CA CA2478542A patent/CA2478542C/fr not_active Expired - Fee Related
- 2003-03-07 AU AU2003242809A patent/AU2003242809B8/en not_active Ceased
- 2003-03-07 JP JP2003576409A patent/JP4648630B2/ja not_active Expired - Fee Related
- 2003-03-07 PE PE2003000234A patent/PE20040155A1/es not_active Application Discontinuation
- 2003-03-07 HR HRP20040824AA patent/HRP20040824B1/hr not_active IP Right Cessation
- 2003-03-07 NZ NZ535147A patent/NZ535147A/en not_active IP Right Cessation
- 2003-03-07 ME MEP-161/08A patent/MEP16108A/xx unknown
- 2003-03-07 CN CNA038053667A patent/CN1656078A/zh active Pending
- 2003-03-07 BR BR0308373-0A patent/BR0308373A/pt not_active IP Right Cessation
- 2003-03-07 WO PCT/FR2003/000752 patent/WO2003078403A2/fr not_active Ceased
- 2003-03-07 EP EP03744396.7A patent/EP1487804B1/fr not_active Expired - Lifetime
- 2003-03-07 CN CN2010102771547A patent/CN101962365A/zh active Pending
- 2003-03-10 AR ARP030100808A patent/AR038915A1/es unknown
- 2003-03-11 US US10/385,871 patent/US6949579B2/en not_active Expired - Lifetime
- 2003-03-11 UY UY27713A patent/UY27713A1/es unknown
- 2003-03-11 GT GT200300057A patent/GT200300057A/es unknown
- 2003-03-11 MY MYPI20030839A patent/MY138269A/en unknown
2004
- 2004-08-05 MA MA27814A patent/MA27230A1/fr unknown
- 2004-08-23 ZA ZA2004/06687A patent/ZA200406687B/en unknown
- 2004-08-31 IL IL163831A patent/IL163831A/en not_active IP Right Cessation
- 2004-09-29 NO NO20044137A patent/NO329384B1/no not_active IP Right Cessation
2010
- 2010-04-06 JP JP2010087830A patent/JP5315287B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
BR0308373A (pt)	2005-01-11
UY27713A1 (es)	2003-09-30
MY138269A (en)	2009-05-29
NO20044137L (no)	2004-11-25
RS79504A (sr)	2006-12-15
AU2003242809A1 (en)	2003-09-29
KR20040091121A (ko)	2004-10-27
AR038915A1 (es)	2005-02-02
CN1656078A (zh)	2005-08-17
RU2345070C2 (ru)	2009-01-27
JP2010222357A (ja)	2010-10-07
IL163831A0 (en)	2005-12-18
ME00058B (me)	2010-10-10
FR2836915B1 (fr)	2008-01-11
PA8568301A1 (es)	2005-02-04
JP5315287B2 (ja)	2013-10-16
CA2478542A1 (fr)	2003-09-25
HRP20040824B1 (hr)	2013-05-31
RS52396B (sr)	2013-02-28
US20040014802A1 (en)	2004-01-22
NZ535147A (en)	2007-08-31
PE20040155A1 (es)	2004-04-18
JP4648630B2 (ja)	2011-03-09
MA27230A1 (fr)	2005-02-01
MXPA04007478A (es)	2004-11-10
WO2003078403A3 (fr)	2004-04-22
CN101962365A (zh)	2011-02-02
TWI329103B (en)	2010-08-21
EP1487804A2 (fr)	2004-12-22
FR2836915A1 (fr)	2003-09-12
JP2005530711A (ja)	2005-10-13
US6949579B2 (en)	2005-09-27
RU2004129780A (ru)	2005-04-10
SV2003001494A (es)	2003-07-10
TW200403226A (en)	2004-03-01
EP1487804B1 (fr)	2014-02-26
GT200300057A (es)	2006-10-19
WO2003078403A2 (fr)	2003-09-25
IL163831A (en)	2010-12-30
KR101068770B1 (ko)	2011-09-30
AU2003242809B2 (en)	2010-03-18
NO329384B1 (no)	2010-10-11
HRP20040824A2 (en)	2005-06-30
CA2478542C (fr)	2012-02-21
JO2326B1 (en)	2006-06-28
AU2003242809B8 (en)	2010-04-15
ZA200406687B (en)	2005-10-26
MEP16108A (en)	2010-06-10

Publication	Publication Date	Title
IL165515A0 (en)	2006-01-15	Bisindolyl-maleimid derivatives as kinase inhibitors
AP2048A (en)	2009-09-24	Diazepinoindole derivatives as kinase inhibitors
PL376129A1 (pl)	2005-12-12	Pochodne pirydazynonu jako inhibitory GSK-3BETA
SI1492785T1 (sl)	2009-06-30	2-hidroksi-3-heteroarilindolni derivati kot inhibitorji GSK3
IL169691A0 (en)	2007-07-04	Malonamide derivatives as gamma-secretase inhibitors
AU2003293356A8 (en)	2004-03-19	Dihydropyridinone derivatives as hne inhibitors
AU2003271566A8 (en)	2004-03-03	Pyrrolopyrazines as kinase inhibitors
ZA200508359B (en)	2009-02-25	Indazole derivatives as JNK inhibitors
EG25482A (en)	2012-01-15	Inhibitors
IL172132A0 (en)	2006-04-10	Thienopyridone derivatives as kinase inhibitors
AU2003278088A1 (en)	2004-05-25	Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors
ZA200702394B (en)	2008-11-26	Indozolone derivatives as 11b-HSD1 inhibitors
IS7717A (is)	2005-02-28	Pýrídasínónafleiður sem PDF4-hemlar
AU2003301302A1 (en)	2004-05-04	Pyradazine compounds as gsk-3 inhibitors
ZA200700181B (en)	2009-03-25	Aryl-pyridine derivatives as 11-beta-HSD1 inhibitors
EP1551801A4 (en)	2007-06-20	NOVEL GAMMA-LACTAMES AS INHIBITORS OF BETA-SECRETASE
PL376789A1 (pl)	2006-01-09	Pochodne aminoindazoli i ich zastosowanie jako inhibitorów kinazy
AU2003302238A8 (en)	2004-06-23	2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors
AU2003249531A1 (en)	2004-02-25	Azaisoquinoline derivatives as matrix metalloproteinase inhibitors
AU2003250482A1 (en)	2004-02-25	Phthalimide derivatives as matrix metalloproteinase inhibitors
IL172375A0 (en)	2009-02-11	Chinazoline derivatives as aurora kinase inhibitors
IL175106A0 (en)	2006-09-05	Novel keto-oxadiazole derivatives as cathepsin inhibitors
AU2003215635A1 (en)	2003-10-13	Thiazol-2-yl-imine compounds as pde-7 inhibitors
AU2003242559A1 (en)	2003-12-19	Alkylaminosiloxanes as corrosion inhibitors
AU2003260908A1 (en)	2004-04-19	Pyrazole derivatives as reverse transcriptase inhibitors